Elicio Therapeutics, Inc.
ELTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $28,312 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1,178 | $1,170 | $1,057 | $1,234 |
| Gross Profit | -$1,178 | -$1,170 | -$1,057 | $27,078 |
| % Margin | – | – | – | 95.6% |
| R&D Expenses | $33,656 | $22,679 | $17,046 | $48,607 |
| G&A Expenses | $11,330 | $11,896 | $0 | $0 |
| SG&A Expenses | $11,330 | $11,896 | $5,630 | $17,778 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,178 | $0 | $0 | $0 |
| Operating Expenses | $43,808 | $34,575 | $22,676 | $66,385 |
| Operating Income | -$44,986 | -$35,745 | -$23,733 | -$39,307 |
| % Margin | – | – | – | -138.8% |
| Other Income/Exp. Net | -$6,912 | $550 | -$4,475 | -$15,266 |
| Pre-Tax Income | -$51,898 | -$35,195 | -$28,208 | -$54,573 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51,898 | -$35,195 | -$28,208 | -$26,401 |
| % Margin | – | – | – | -93.2% |
| EPS | -4.25 | -6.96 | -9.1 | -19.32 |
| % Growth | 38.9% | 23.5% | 52.9% | – |
| EPS Diluted | -4.25 | -6.96 | -9.1 | -19.32 |
| Weighted Avg Shares Out | 12,203 | 5,056 | 3,100 | 3,200 |
| Weighted Avg Shares Out Dil | 12,203 | 5,056 | 3,100 | 3,200 |
| Supplemental Information | – | – | – | – |
| Interest Income | $777 | $373 | $65 | $3 |
| Interest Expense | $455 | $1,059 | $3,596 | $876 |
| Depreciation & Amortization | $1,178 | $1,170 | $1,057 | $801 |
| EBITDA | -$50,265 | -$32,966 | -$23,554 | -$51,925 |
| % Margin | – | – | – | -183.4% |